• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Adagio Medical Holdings Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/12/25 4:05:24 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email
    ADAGIO MEDICAL HOLDINGS, INC._November 12, 2025
    0002006986false00020069862025-11-122025-11-12

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): November 12, 2025

    ​

    ADAGIO MEDICAL HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

    001-42199

    99-1151466

    (State or other jurisdiction of incorporation)

    (Commission File Number)

    (I.R.S. Employer Identification No.)

    ​

    26051 Merit Circle, Suite 102
    Laguna Hills, CA

        

    92653

    (Address of principal executive offices)

        

    (Zip Code)

    ​

    (949) 348-1188

    (Registrant’s telephone number, including area code)

    ​

    Not Applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    Trading
    Symbol(s)

    Name of each exchange
    on which registered

    Common Stock, par value $0.0001 per share

    ADGM

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

    ​

    Emerging growth company ☒

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    Item 2.02. Results of Operations and Financial Condition.

    On November 12, 2025, Adagio Medical Holdings, Inc. (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025, and providing a business update. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

    The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    ​

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    ​

    ​

    ​

    Exhibit No.

        

    Description

    99.1

    ​

    Press Release, dated November 12, 2025

    104

    ​

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ​

    ​

    ​

    2

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: November 12, 2025

    ​

    ​

    ​

    ​

    ​

        

    Adagio Medical Holdings, Inc.

    ​

    ​

     

    ​

    ​

    By:

    /s/ Deborah Kaster

    ​

    ​

    Name:

    Deborah Kaster

    ​

    ​

    Title:

    Chief Financial Officer and Chief Business Officer

    ​

    ​

    ​

    ​

    ​

    ​

    3

    Get the next $ADGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference

    Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY. Presentation Information A live and recorded webcast of the presentation will be available at: https://event.webcasts.com/starthere.jsp?ei=1742138&tp_key=f2a06e9abc About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizi

    11/5/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia

    Proceeds Expected to Fund Ongoing Development and Submission Activities to Support FDA Evaluation of Company's First and Next Generation Proprietary Ultralow Cryoablation Technologies Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-50-million-private-placement), led by existing investors and new healthcare-dedicated institutional investors. Adagio intends to deploy the net proceeds to: Sup

    10/20/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    SEC Filings

    View All

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc

    SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/25 9:04:35 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Adagio Medical Holdings Inc

    424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    11/12/25 4:10:28 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Adagio Medical Holdings Inc

    424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    11/12/25 4:11:37 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Perceptive Advisors Llc

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    10/22/25 4:33:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Kaster Deborah

    3 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    9/30/25 6:01:40 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider George Dan

    3 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    4/28/25 5:23:28 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    View All

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Deborah Kaster as Chief Business Officer

    Adagio Medical (NASDAQ:ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector. Most recently, Kaster served as Vice President of Investor Relations at Shockwave Medical, where she played a pivotal role in the company's growth from IPO to its acquisition by Johnson & Johnson. During her time at Shockwave, the company's stock price appreciated nearly 2000%, a testame

    3/31/25 4:01:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director

    Founding Chief Executive Officer and Director Olav Bergheim to Depart Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company" or "Adagio")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer ("CEO") and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrently, the Company announced the appointment of Todd Usen, as Chief Executive Officer and Director of the Company and Orly Mishan, as Chairperson of the Board of Directors, effective December 13, 2024. Mr. Bergheim will serve as an advisor to the Company and will support Mr. Usen

    12/16/24 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/24 4:30:17 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    8/12/24 4:22:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care